Brief: FibroGen Announces Positive Type C Meeting With The FDA For Roxadustat In Patients With Anemia Associated With Lower-Risk Myelodysplastic Syndromes
07/08/2025 13:34
Aug 7 (Reuters) - FibroGen Inc FGEN.O: FIBROGEN ANNOUNCES POSITIVE TYPE C MEETING WITH THE FDA FOR ROXADUSTAT IN PATIENTS WITH ANEMIA ASSOCIATED WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES Source text: ID:nGNX88J1Yq Further company coverage: FGEN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kyntra Bio
See all newsBrief: Kyntra Bio Appoints Andrew E. Singer, Mba To Its Board Of Directors
NASDAQ RESUMED AT 01:28 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:23 PM
Kyntra Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kyntra Bio swings to profit in Q2 on deconsolidation of subsidiary